MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...

MBX生物科学宣布，其Phase 1单次和多次递增剂量试验中最后一名受试者的最后一次访问已完成，该试验的药物MBX 1416是一种正在开发用于治疗的开多类胰高血糖素样肽1受体拮抗剂……

Benzinga · 2024/11/18 21:19

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of Post-Bariatric Hypoglycemia

MBX生物科学公司宣布，MBX 1416的1期单剂量和多剂量递增试验中最后一名受试者的最后一次访视已完成，该药物是公司正在开发用于治疗减重手术后低血糖的长效胰高血糖素样肽1受体拮抗剂。

MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the completion of the last subject's last visit in its Phase 1 single and multiple ascending dose trial of MBX 1416, the Company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist in development for the treatment of post-bariatric hypoglycemia (PBH).

MBX生物科学公司（纳斯达克：MBX）是一家专注于发现和开发新型精确肽疗法以治疗内分泌和代谢疾病的临床阶段生物制药公司，今天宣布其MBX 1416的1期单剂量和多剂量递增试验中最后一名受试者的最后一次访视已完成，该药物是公司正在开发用于治疗减重手术后低血糖（PBH）的长效胰高血糖素样肽1（GLP-1）受体拮抗剂。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of...

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of Post-Bariatric Hypoglycemia

MBX Biosciences Announces The Completion Of The Last Subject's Last Visit In Its Phase 1 Single And Multiple Ascending Dose Trial Of MBX 1416, The Company's Long-Acting Glucagon-Like Peptide 1 Receptor Antagonist In Development For The Treatment Of Post-Bariatric Hypoglycemia

MBX生物科学公司宣布，MBX 1416的1期单剂量和多剂量递增试验中最后一名受试者的最后一次访视已完成，该药物是公司正在开发用于治疗减重手术后低血糖的长效胰高血糖素样肽1受体拮抗剂。

风险及免责提示

声明